{"id":"NCT00256867","sponsor":"GlaxoSmithKline","briefTitle":"A Study In Patients With Type 2 Diabetes Mellitus","officialTitle":"A 16 Week Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication (GSK523338) to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08-18","primaryCompletion":"2006-10-31","completion":"2006-10-31","firstPosted":"2005-11-22","resultsPosted":"2018-03-23","lastUpdate":"2018-07-02"},"enrollment":369,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":null,"primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"GSK523338","otherNames":[]}],"arms":[],"summary":"This study evaluates the effect of medicines for type 2 diabetes and lipids control. This study will require about 6 office visits for lab tests and examinations. All study related medicines and medical examinations will be provided at no cost to the subjects.","primaryOutcome":{"measure":"Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy","timeFrame":"Baseline (Week 0) and Week 6","effectByArm":[{"arm":"All FDC RSG/SIMV Groups","deltaMin":-39.9,"sd":null},{"arm":"All RSG Monotherapy Groups","deltaMin":5.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":85,"countries":["United States","Australia","Canada","Mexico","Philippines","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["Headache","Hypertension","Arthralgia","Upper respiratory tract infection"]}}